United StatesÚltimas notícias

Nexxen International (NASDAQ:NEXN), a global advertising technology platform, reported record-breaking financial results for the first quarter of 2026.

Kornit Digital (NASDAQ:KRNT), a leading provider of digital textile printing technology, announced its first-quarter 2026 financial results.

Caesarstone (NASDAQ:CSTE) reported first-quarter 2026 results that highlighted the early fruits of its structural reorganization.

Beasley Broadcast Group (NASDAQ:BBGI) reported a complex first quarter for 2026, where a return to statutory profitability was accompanied by persistent headwinds in traditional agency advertising.

Similarweb (NYSE:SMWB) reported a significant improvement in its financial health for the first quarter of 2026, swinging to a non-GAAP operating profit as the company scales its footprint among high-value enterprise clients.

Dominari Holdings (NASDAQ:DOMH) revealed a massive acceleration in its business for the first quarter of 2026, fueled by a resurgence in investment banking and underwriting activity.

Riskified (NYSE:RSKD) reported first-quarter 2026 financial results that showcased resilient demand for its AI-driven fraud management platform.

Eos Energy Enterprises (NASDAQ:EOSE) kicked off fiscal year 2026 with an aggressive acceleration in manufacturing output and a transformative strategic partnership.

Dynatrace (NYSE:DT) announced record financial results for its fourth quarter and full fiscal year 2026, officially surpassing the $2 billion mark in annual recurring revenue (ARR).

Voyager Therapeutics (NASDAQ:VYGR) achieved a critical regulatory milestone this week, presenting positive three-month toxicology data for its lead Alzheimer’s disease candidate, VY1706.

Global-e Online (NASDAQ:GLBE) reported a pivotal shift in its financial performance for the first quarter of 2026, swinging to a GAAP net profit as its cross-border e-commerce platform captured a record volume of international trade.

Zenas BioPharma (NASDAQ:ZBIO) announced that it is on track to transition into a commercial-stage company, with plans to submit its first Biologics License Application (BLA) to the U.S. Food and Drug Administration this quarter.